Monthly information regarding the total number of voting rights and shares comprising the
share capital
Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF


Paris, August 29, 2025,

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com



Number of shares comprising Total number of voting rights
Date
the capital in circulation (1) (2)
Gross Total Net Total
July 31, 2025 83,017,167 84,117,041 84,117,041



Including 1,100,000 new shares issued during the month as part of the equity financing facility (see press releases published
on July 25, 2024 and April 24, 2025).
(1)The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In
accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares
carrying voting rights, including shares without voting rights.
(2)
The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the
shares with suspended voting rights. It is published for proper public information in accordance with the AMF
recommendation of July 17, 2007.


***

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-
time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they
happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio®
platform is used globally across a wide range of medical specialties and is making a transformative change in
the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.


Mauna Kea Technologies NewCap - Investor Relations
investors@maunakeatech.com Aurélie Manavarere / Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu



1